Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring recurrent adult brain tumor
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven tumors: Unresectable meningioma Atypical meningioma Malignant meningioma Angioblastic meningioma Hemangiopericytoma Recurrent or progressive, unresectable tumor after failing radiation therapy or refused radiation therapy following 2 surgeries PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky at least 60% Life expectancy: At least 3 months Hematopoietic: AGC at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: SGPT less than 2.0 times normal Alkaline phosphatase less than 2.0 times normal Bilirubin less than 1.5 mg/dL Renal: BUN less than 1.5 times normal OR Creatinine less than 1.5 times normal Other: No active infection No diseases that obscure toxicity or dangerously alter drug metabolism No serious intercurrent medical illness Not pregnant Fertile patients must use adequate contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy: Prior chemotherapy allowed and recovered from all myelotoxicity secondary to the therapy Endocrine therapy: Prior hormonal therapy allowed No concurrent hormonal therapy Radiotherapy: Prior radiotherapy allowed Surgery: Not specified
Sites / Locations
- University of Texas - MD Anderson Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Arm 1: Benign Meningiomas
Arm 2: Other Pathologies
INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
INF alpha as subcutaneous injection Monday to Friday for 8 weeks.